Enteral supplementation with arachidonic and docosahexaenoic acid and pulmonary outcome in extremely preterm infants.

[1]  A. Boutin,et al.  Association Between Enteral Supplementation With High-Dose Docosahexaenoic Acid and Risk of Bronchopulmonary Dysplasia in Preterm Infants , 2023, JAMA network open.

[2]  S. Moltu,et al.  Effect of arachidonic and docosahexaenoic acid supplementation on respiratory outcomes and neonatal morbidities in preterm infants. , 2022, Clinical nutrition.

[3]  Y. Chang,et al.  Comparison of definitions of bronchopulmonary dysplasia to reflect the long-term outcomes of extremely preterm infants , 2022, Scientific Reports.

[4]  L. Doyle,et al.  Neonatal Docosahexaenoic Acid in Preterm Infants and Intelligence at 5 Years. , 2022, The New England journal of medicine.

[5]  E. Schuit,et al.  Comparison of new bronchopulmonary dysplasia definitions on long term outcomes in preterm infants. , 2022, The Journal of pediatrics.

[6]  C. Bührer,et al.  Population-Based Outcome Data of Extremely Preterm Infants in Germany during 2010–2017 , 2022, Neonatology.

[7]  V. Bhandari,et al.  Diagnosis and management of bronchopulmonary dysplasia , 2021, BMJ.

[8]  P. Agarwal,et al.  New BPD-prevalence and risk factors for bronchopulmonary dysplasia/mortality in extremely low gestational age infants ≤28 weeks , 2021, Journal of Perinatology.

[9]  Lois E. H. Smith,et al.  Effect of Enteral Lipid Supplement on Severe Retinopathy of Prematurity , 2021, JAMA pediatrics.

[10]  S. Ohga,et al.  Trends in Bronchopulmonary Dysplasia among Extremely Preterm Infants in Japan, 2003-2016. , 2020, The Journal of pediatrics.

[11]  A. Duttaroy,et al.  Maternal Docosahexaenoic Acid Status during Pregnancy and Its Impact on Infant Neurodevelopment , 2020, Nutrients.

[12]  V. Fanos,et al.  The Docosahexanoic Acid: From the Maternal-Fetal Dyad to Early Life Toward Metabolomics , 2020, Frontiers in Pediatrics.

[13]  A. Synnes,et al.  Effect of Maternal Docosahexaenoic Acid Supplementation on Bronchopulmonary Dysplasia-Free Survival in Breastfed Preterm Infants: A Randomized Clinical Trial. , 2020, JAMA.

[14]  A. Hellström,et al.  Docosahexaenoic Acid and Arachidonic Acid Levels Are Associated with Early Systemic Inflammation in Extremely Preterm Infants , 2020, Nutrients.

[15]  E. Ota,et al.  Docosahexaenoic acid and bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis , 2020, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[16]  E. Jensen,et al.  Lifelong pulmonary sequelae of bronchopulmonary dysplasia. , 2020, Current opinion in pediatrics.

[17]  Bing Zhang,et al.  Arachidonic acid inhibits inflammatory responses by binding to myeloid differentiation factor-2 (MD2) and preventing MD2/toll-like receptor 4 signaling activation. , 2020, Biochimica et biophysica acta. Molecular basis of disease.

[18]  B. Poindexter,et al.  The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants. An Evidence-based Approach , 2019, American journal of respiratory and critical care medicine.

[19]  K. Maršál,et al.  Association Between Year of Birth and 1-Year Survival Among Extremely Preterm Infants in Sweden During 2004-2007 and 2014-2016 , 2019, JAMA.

[20]  S. McGrath-Morrow,et al.  Bronchopulmonary dysplasia: what are its links to COPD? , 2019, Therapeutic advances in respiratory disease.

[21]  P. Lumbiganon,et al.  The global epidemiology of preterm birth. , 2018, Best practice & research. Clinical obstetrics & gynaecology.

[22]  T. Raju,et al.  Bronchopulmonary Dysplasia: Executive Summary of a Workshop , 2018, The Journal of pediatrics.

[23]  S. Dyall,et al.  Extremely preterm infants receiving standard care receive very low levels of arachidonic and docosahexaenoic acids. , 2017, Clinical nutrition.

[24]  P. Davis,et al.  Docosahexaenoic Acid and Bronchopulmonary Dysplasia in Preterm Infants , 2017, The New England journal of medicine.

[25]  Camilia R. Martin,et al.  Fatty acid requirements for the preterm infant. , 2017, Seminars in fetal & neonatal medicine.

[26]  S. Carlson,et al.  Docosahexaenoic Acid and Arachidonic Acid Nutrition in Early Development. , 2016, Advances in pediatrics.

[27]  W. Harris,et al.  What is the relationship between gestational age and docosahexaenoic acid (DHA) and arachidonic acid (ARA) levels? , 2015, Prostaglandins, leukotrienes, and essential fatty acids.

[28]  W. Harris,et al.  Beyond Building Better Brains: Bridging the Docosahexaenoic acid (DHA) Gap of Prematurity , 2014, Journal of Perinatology.

[29]  S. Freedman,et al.  Resolvin D1 and Lipoxin A4 Improve Alveolarization and Normalize Septal Wall Thickness in a Neonatal Murine Model of Hyperoxia-Induced Lung Injury , 2014, PloS one.

[30]  C. Serhan,et al.  Resolvins and protectins in inflammation resolution. , 2011, Chemical reviews.

[31]  A. Greenough,et al.  Prediction of bronchopulmonary dysplasia , 2011, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[32]  R. Brant,et al.  A Time‐Based Analysis of Inflammation in Infants at Risk of Bronchopulmonary Dysplasia , 2018, The Journal of pediatrics.

[33]  E. Bancalari,et al.  Bronchopulmonary dysplasia. , 2001, American journal of respiratory and critical care medicine.